Sparebank 1 SMN
The equity certificates purchased by SpareBank 1 SMN on 5 and 8 February for use in the group’s savings programme for employees, have been distributed to the employees as bonus equity certificates in accordance with their savings amount.
After allocation the bank owns 2,095 equity certificates.
As participants in the savings programme, the primary insiders below have been allocated equity certificates as follows:
| Name: | Allocated no. ECC’s: | New total holding of ECC’s*: |
| Cathrine Aunvik | 123 | 2,005 |
| Rolf Jarle Brøske Tomm Bøyesen Kjell Fordal | 123 123 123 | 10,328 6,367 246,427 |
| Vegard Helland | 123 | 35,317 |
| Kjersti Hønstad | 123 | 5,029 |
| Inge Lindseth Nelly Maske Ola Neråsen Arne Nypan Kjetil Reinsberg Margrethe L. Resellmo Berit Rustad Camilla Stang Christina Straub | 123 123 123 123 123 31 123 31 31 | 9,028 21,258 42,879 26,813 28,474 535 4,090 535 789 |
*) incl. close associates
Trondheim, 10 February 2021
Contact person in SpareBank 1 SMN:
CFO, Kjell Fordal, tel. 905 41 672
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Robex Resources Inc.21.12.2025 23:28:03 CET | Press release
Robex Pours First Gold at Kiniéro on Schedule and Budget
ALK Abello19.12.2025 22:46:46 CET | Press release
Major shareholder announcement
ALK Abello19.12.2025 22:46:46 CET | Pressemeddelelse
Storaktionærmeddelelse
Zealand Pharma19.12.2025 22:00:00 CET | Press release
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Boehringer Ingelheim Limited19.12.2025 21:10:00 CET | Press release
U.S. FDA approves JASCAYD® (nerandomilast) tablets for the treatment of progressive pulmonary fibrosis in adults
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
